Dr CHITRA JOSEPH CHITRA.JOSEPH@NOTTINGHAM.AC.UK
Research Fellow
The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
Joseph, Chitra; Alsaleem, Mansour A.; Toss, Michael S.; Kariri, Yousif A.; Althobiti, Maryam; Alsaeed, Sami; Aljohani, Abrar I.; Narasimha, Pavan L.; Mongan, Nigel P.; Green, Andrew R.; Rakha, Emad A.
Authors
Mansour A. Alsaleem
Michael S. Toss
Yousif A. Kariri
Maryam Althobiti
Sami Alsaeed
Abrar I. Aljohani
Pavan L. Narasimha
NIGEL MONGAN nigel.mongan@nottingham.ac.uk
Associate Pro-Vice Chancellorglobal Engagement
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Emad A. Rakha
Abstract
Background: The leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) plays a role in immune response homeostasis, extracellular matrix remodelling and it is overexpressed in many high-grade cancers. This study aimed to elucidate the biological and prognostic role of LAIR-1 in invasive breast cancer (BC). Methods: The biological and prognostic effect of LAIR-1 was evaluated at the mRNA and protein levels using well-characterised multiple BC cohorts. Related signalling pathways were evaluated using in silico differential gene expression and siRNA knockdown were used for functional analyses. Results: High LAIR-1 expression either in mRNA or protein levels were associated with high tumour grade, poor Nottingham Prognostic Index, hormone receptor negativity, immune cell infiltrates and extracellular matrix remodelling elements. High LAIR-1 protein expression was an independent predictor of shorter BC-specific survival and distant metastasis-free survival in the entire BC cohort and human epidermal growth factor receptor 2 (HER2)+ subtype. Pathway analysis highlights LAIR-1 association with extracellular matrix remodelling-receptor interaction, and cellular proliferation. Depletion of LAIR-1 using siRNA significantly reduced cell proliferation and invasion capability in HER2+ BC cell lines. Conclusion: High expression of LAIR-1 is associated with poor clinical outcome in BC. Association with immune cells and immune checkpoint markers warrant further studies to assess the underlying mechanistic roles.
Citation
Joseph, C., Alsaleem, M. A., Toss, M. S., Kariri, Y. A., Althobiti, M., Alsaeed, S., …Rakha, E. A. (2020). The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. Cancers, 13(1), 1-19. https://doi.org/10.3390/cancers13010080
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 24, 2020 |
Online Publication Date | Dec 30, 2020 |
Publication Date | Dec 30, 2020 |
Deposit Date | Jan 5, 2021 |
Publicly Available Date | Jan 6, 2021 |
Journal | Cancers |
Electronic ISSN | 2072-6694 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 1 |
Article Number | 80 |
Pages | 1-19 |
DOI | https://doi.org/10.3390/cancers13010080 |
Keywords | Cancer Research; Oncology |
Public URL | https://nottingham-repository.worktribe.com/output/5184252 |
Publisher URL | https://www.mdpi.com/2072-6694/13/1/80 |
Files
Cancers-13-00080
(3.3 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search